- William Huyett Appointed to Chief Operating Officer -
- Gina Consylman Promoted to Senior Vice President, Chief Financial
Officer -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology
company, today announced the appointment of William Huyett as chief
operating officer and the promotion of Gina Consylman to senior vice
president and chief financial officer.
"Strengthening our leadership team with these key appointments is
critical for Ironwood as we seek to execute on our strategy to deliver
rapid top-line growth and advance our innovative mid- to late-stage
product candidates," said Peter Hecht, chief executive officer at
Ironwood. "Bill is a seasoned, strategic business partner who has a
remarkable breadth of experience that will further strengthen our
ability to build a successful and innovative company. Gina has been an
invaluable finance and enterprise leader at Ironwood over the past three
years and I am confident she will have an even greater impact in her
expanded role. We are committed to attracting and developing leaders
with great strategic judgment, absolute integrity, and an owner-oriented
mindset. Bill and Gina exemplify these qualities and I am thrilled to
have them as part of the executive team to drive our company forward."
Mr. Huyett brings to Ironwood extensive experience in corporate
strategy, capital allocation, finance, product
development/commercialization and corporate leadership in the life
sciences industry and many other business sectors. At Ironwood, he will
be responsible for the company's finance, corporate strategy, corporate
development, global operations, investor relations and corporate
communications functions. Mr. Huyett joins Ironwood following a
distinguished 30-year career at McKinsey and Company, Inc., where he
served global clients in the life sciences, industrial and other
technology-intensive sectors. Most recently, he has been a senior
partner emeritus at McKinsey. He was a leader in the firm's
pharmaceutical and medical products and its strategy and corporate
finance practices, and served on McKinsey's Shareholder's Council (its
board of directors), serving as chair of its Finance Committee. Prior to
joining McKinsey, Mr. Huyett held a variety of line management positions
with Allen-Bradley (now Rockwell Automation, Inc.). Mr. Huyett serves on
the board of directors of the London Stock Exchange-listed Georgia
Healthcare Group PLC. He also serves on several not-for-profit boards,
including The Rockefeller University, the Marine Biological Laboratory,
the University of Virginia Darden School of Business and the YMCA of
Greater Boston. He earned his B.S. in electronics engineering and his
M.B.A. from the University of Virginia.
Ms. Consylman is a 25-year veteran in the field of corporate finance.
She joined Ironwood in 2014 and currently provides oversight of the
company's finance, planning, accounting, tax, treasury and insurance
functions. Prior to joining Ironwood, she was vice president, corporate
controller and principal accounting officer at Analogic Corporation,
served as senior director, corporate accounting at Biogen Inc., and as
corporate controller at Varian Semiconductor Equipment Associates, Inc.
A Certified Public Accountant, Ms. Consylman began her career in public
accounting at Ernst & Young LLP. She holds a B.S. in accounting from
Johnson & Wales University and a M.S. in taxation from Bentley
University.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ:IRWD) is a commercial biotechnology
company focused on creating medicines that make a difference for
patients, building value for our fellow shareholders, and empowering our
passionate team. We are commercializing two innovative primary care
products: linaclotide, the U.S. branded prescription market leader for
adults with irritable bowel syndrome with constipation (IBS‐C) or
chronic idiopathic constipation (CIC), and lesinurad, which is approved
for the treatment of hyperuricemia associated with gout in patients who
have not achieved target serum uric acid (sUA) levels with a medically
appropriate daily dose of a xanthine oxidase inhibitor (XOI) alone. We
are also advancing a pipeline of innovative product candidates in areas
of significant unmet need, including uncontrolled gastroesophageal
reflux disease, diabetic nephropathy, heart failure with preserved
ejection fraction, achalasia and sickle cell disease. Ironwood was
founded in 1998 and is headquartered in Cambridge, Mass. For more
information, please visit www.ironwoodpharma.com
or www.twitter.com/ironwoodpharma;
information that may be important to investors will be routinely posted
in both these locations.
This press release contains forward-looking statements. Investors are
cautioned not to place undue reliance on these forward-looking
statements, including statements about Ironwood's leadership team, the
strength and value thereof, and the leadership team's impact on the
company and its business, growth, business strategy, pipeline
advancement, productivity and the potential of its products and product
candidates and their impact, as well as statements about the timing of
any of the foregoing. Each forward‐looking statement is subject
to risks and uncertainties that could cause actual results to differ
materially from those expressed or implied in such statement. Applicable
risks and uncertainties include those related to management and
executive appointments; our ability to effectively advance our strategy;
the effectiveness of development and commercialization efforts by us and
our partners; preclinical and clinical development, manufacturing and
formulation development; the risk that findings from our completed
nonclinical and clinical studies may not be replicated in later studies;
efficacy, safety and tolerability of linaclotide, lesinurad and our
product candidates; decisions by regulatory authorities; the risk that
we are unable to successfully integrate lesinurad into our existing
business, commercialize lesinurad or realize the anticipated benefits of
the lesinurad transaction; the risk that we may never get sufficient
patent protection for our products and our product candidates or that we
are not able to successfully protect such patents; the outcomes in legal
proceedings to protect or enforce the patents relating to our products
and product candidates, including ANDA litigation; developments in the
intellectual property landscape; challenges from and rights of
competitors or potential competitors; the risk that our planned
investments do not have the anticipated effect on our company revenues,
linaclotide, lesinurad or our product candidates; the risk that we are
unable to manage our operating expenses or cash use for operations, or
are unable to commercialize our products, within the guided ranges or
otherwise as expected and those risks listed under the heading "Risk
Factors" and elsewhere in Ironwood's Quarterly Report on Form 10-Q for
the quarter ended September 30, 2017, and in our subsequent SEC filings.
These forward-looking statements (except as otherwise noted) speak only
as of the date of this press release, and Ironwood undertakes no
obligation to update these forward-looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171128005464/en/
Investor and Media Relations
Ironwood Pharmaceuticals, Inc.
Meredith
Kaya, 617-374-5082
Senior Director, Investor Relations and
Corporate Communications
mkaya@ironwoodpharma.com
Source: Ironwood Pharmaceuticals, Inc.
News Provided by Acquire Media